HCA Healthcare enters its July 24 earnings report under fresh pressure — down 14% on the week, with options traders buying protection at the most aggressive pace in a year.
The clearest signal this week is in the options market. The put/call ratio hit 1.25 on July 14, more than three standard deviations above its 20-day average of 0.72. That is the highest defensive reading of the past year, just short of the 52-week peak of 1.33. The message is unambiguous: investors are paying up for downside hedges ahead of next Thursday's print. The stock closed at $363.60, down nearly 7% on Tuesday alone, extending a brutal week across the hospital sector. Close peers THC and UHS fell 12% and 11% respectively on the week, confirming this is a sector-wide repricing rather than an HCA-specific story — though HCA's 14% decline outpaced both.
Short interest tells a quieter story than the options market. At 2.5% of free float, short positioning is modest. It has crept up roughly 5% over the past week and 32% over the past month — a meaningful build in proportional terms, but the absolute level remains low. The borrow market is essentially open: availability is running at over 1,200% relative to shares already borrowed, meaning there is no constraint on new short positions. Cost to borrow is just 0.43%, among the lowest levels of the past six weeks. The squeeze risk is negligible. Shorts are not driving this decline — they are gently adding to a move that longs are causing.
The Street has moved decisively in one direction over the past week, and the speed is notable. RBC Capital cut its target from $534 to $435 on July 15 while keeping its Outperform rating. Keybanc trimmed from $510 to $475, also maintaining Overweight. Those two followed Wells Fargo's cut to $428 on July 13 and Barclays' downgrade — from Overweight to Equal-Weight with a target drop to $427 — on July 8. The consensus mean now stands at $471, implying roughly 29% upside from current levels. Bulls point to HCA's operational track record and market share gains in high-growth regions. Bears flag Medicaid reimbursement risk, persistent cost headwinds, and the low visibility management has offered on exchange-driven volume trends. The forward earnings multiple sits near 12x — not cheap for a business facing margin pressure, but not stretched either given the cash generation profile.
History adds a cautionary note for the earnings setup. The April 24 Q1 print resulted in a 6% single-day decline, with the stock off more than 8% over the following week. That was the most recent earnings reaction in the data, and it arrived when sentiment was arguably less defensive than it is today. The EPS surprise factor score of 63 suggests HCA has a reasonable record of beating estimates — but the April reaction showed that beating the number is not sufficient if guidance disappoints or management commentary on Medicaid volumes is unclear.
With the July 24 print now nine days away, the key variable is whether management can provide enough clarity on reimbursement trends and volume outlook to offset the Street's growing caution — or whether the options market's elevated put demand proves well-placed.
See the live data behind this article on ORTEX.
Open HCA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
